Larazotide vs Teduglutide
How Larazotide and Teduglutide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Larazotide and Teduglutide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Larazotide vs Teduglutide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Larazotide | Teduglutide |
|---|---|---|
| What it is | Synthetic octapeptide (an 8-amino-acid tight-junction regulator, taken by mouth) | GLP-2 receptor agonist (a recombinant analog of the gut hormone glucagon-like peptide-2) |
| Class / category | Healing / recovery | Healing / recovery |
| Evidence tier | Human RCT · Mixed | Human RCT · Helped |
| Studied / approved for | Celiac disease (persistent symptoms despite a gluten-free diet); Reducing intestinal permeability ('leaky gut'); COVID-19-related conditions (MIS-C, long COVID) — early investigation | Short bowel syndrome in adults and pediatric patients 1 year and older who depend on parenteral support |
| US regulatory status (2026) | investigational (as of Jul 2026) | fda approved (as of Jul 2026) — approved for Short bowel syndrome in adults and pediatric patients 1 year and older who depend on parenteral support |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | 29 | No data |
| Banned in sport (WADA) | Unknown | Unknown |
| Key risks | In its clinical trials larazotide was generally well tolerated, which fits its design — it acts locally in the gut and is minimally absorbed, so it doesn't circulate through the body the way an injected peptide does. The most commonly reported side effects were headache and gastrointestinal symptoms, at rates often close to placebo. Because no larazotide product was ever approved, there is no long-term, post-market human safety record, and any "larazotide" sold outside a trial is an unregulated research product of unknown purity. | Teduglutide has substantial human safety data, but its growth-promoting action creates a serious trade-off. The FDA label warns that it may accelerate neoplastic growth and reports intestinal polyps, requiring colonoscopy and upper-GI surveillance. Other important risks include intestinal obstruction, gallbladder or pancreatic disease, fluid overload, and increased absorption of oral medicines. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Larazotide vs Teduglutide: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want an FDA-approved, prescribable option
Leans toward Teduglutide
Teduglutide is FDA-approved (as of Jul 2026); Larazotide is investigational in the US, so it isn't available as an approved prescription.
References
- 1.Larazotide — indexed research (PubMed, National Library of Medicine)
- 2.Larazotide — registered clinical studies (ClinicalTrials.gov)
- 3.CeDLara — Phase 3 larazotide acetate in celiac disease (NCT03569007, terminated)
- 4.Larazotide acetate — Phase 2b in celiac disease (NCT01396213)
- 5.Larazotide (AT-1001) — compound record (PubChem CID 9810532)
- 6.Gattex (teduglutide) prescribing information